Evaluating use characteristics for the oncotype Dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer

Journal of Oncology Practice

Volumn 9, Issue 4, 2013, Pages 182-187

  Chen, Clara ^b   Dhanda, Rahul ^b   Tseng, Wan Yu ^b   Forsyth, Michael ^b   Patt, Debra A ^a  

^a Texas Oncology   (United States)

^b Rocky Mountain Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVALUATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; ONCOTYPE DX 21 GENE RECURRENCE SCORE; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TRANSCRIPTOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84887087050     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000638     Document Type: Article

References (31)

1. Lo SS, Mumby PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
2. Bast RC J.r., Ravdin P, Hayes D.F., et al.: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
3. Eifel P, Axelson JA, Costa J, et al.: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
4. Carlson RW, Edge SB, Theriault RL: NCCN: Breast cancer. Cancer Contr 854-861 (suppl 2), 2001
5. Goldhirsch A, Wood WC, Gelber R.D., et al.: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
6. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
7. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
8. Paik S, Shak S, Tang G., et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
9. Genomic Health: What is the Oncotype DX test? http://www.oncotypedx.com/ Breast/PatientsCaregiversInvasive
10. Harris L, Fritsche H, Mennel R., et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
11. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology, breast cancer, (Version 2.2008) http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#breast
12. Mamounas EP, Tang G, Fisher B., et al.: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSAPB B-14 and NSABP B-20. J Clin Oncol 29:1677-1683, 2010
13. Habel LA, Shak S, Jacobs M.K., et al: Apopulation-based studyoftumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006
14. Lyman GH, Kuderer NM: Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: A metaanalysis. Clin Breast Can 7:372-379, 2006
15. Swain SM: A step in the right direction. J Clin Oncol 24:3717-3718, 2006
16. Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12:631-635, 2007
17. Albain KS, Barlow WE, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
18. Oratz R, Paul D, Cohn A.L., et al.: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3:182-186, 2007
19. Asad J, Jacobson AF, Estabrook A, et al.: Does RS recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196:527-529, 2008
20. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332-7341, 2005
21. Cartwright TH, Yim YM, Yu E, et al.: Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US Community Oncology. Clin Colorectal Cancer [epub ahead of print on June 21, 2012]
22. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
23. Tang G, Shak S, Paik S., et al.: Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant! For women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127:133-142, 2011
24. Muehlenbein CE, Hoverman JR, Gruschkus, et al.: Evaluation of the reliability of electronic medical record data in identifying comorbid conditions among patients with advanced non-small cell lung cancer. J Clin Epidemiol 2011:983271 2011 Epub 2011 May
25. Nadler E, Yu E, Ravelo A., et al.: Bevacizumab treatment to progression after chemotherapy: Outcomes from a U.S. community practice network. Oncologist 16:486-496, 2011
26. Beveridge R, Satram-Hoang S, Sail K., et al.: Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma 52:2117-2123,2011
27. Carlson RW, Brown E, Burstein H.J., et al.: NCCN Task Force report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 4:S1-S26, 2006 (suppl 1)
28. Klang N, Liebermann S, Rizel N., et al.: The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel. J Clin Oncol 28:15s, 2010 (suppl; abstr 6075)
29. Kazzaz DR, Chen C, Shankelton M.T., et al.: Evaluation of relation between Oncotype Dx recurrence score and adjuvant chemotherapy administration. J Clin Oncol 9, 2011 (suppl; abstr e11105)
30. Hornberger J, Chien R, Krebs K., et al.: US insurance program's experience with a multigene assay for early-stage breast cancer. J Oncol Pract 7:e38s-e45s, 2011 (suppl 3)
31. Lieberman N, Baehner FL, Soussan-Gutman L, et al.: Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort. J Clin Oncol 29:78s, 2011 (suppl; abstr 632)